试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-18
Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19
编号:NCT04360759登记状态:入组前撤回企业 / 申办者:University of Cape Town
药物 / 成分:Chloroquine or hydroxychloroquine
登记的停止原因(原文):Equipoise for hydroxychloquine was lost
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-17
Preoperative Oral ImmunoNuTrition to Improve Surgical Outcomes for IBD Patients (PINT)
编号:NCT03333148登记状态:入组前撤回企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Nestle IMPACT Immunonutrition、Arm B- Standard of Care
登记的停止原因(原文):never enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-17
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
编号:NCT03488810登记状态:入组前撤回企业 / 申办者:European Organisation for Research and Treatment of Cancer - EORTC
药物 / 成分:Radiation Therapy、Apalutamide、Luteinising Hormone Releasing Hormone analog agonist (LHRHa)、Non-steroidal anti-androgen
登记的停止原因(原文):Extended study timelines and additional budget could no longer be supported.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-17
Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Ethiopia
编号:NCT04171388登记状态:入组前撤回企业 / 申办者:Brigham and Women's Hospital
药物 / 成分:Azithromycin 500 mg、Multiple Micronutrient or Fortified Balanced Energy Protein Supplement、Placebo oral tablet 500 mg、Enhanced Infection Management Package (EIMP)
登记的停止原因(原文):Trial withdrawn due to COVID-19.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-14
Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
编号:NCT03371862登记状态:入组前撤回企业 / 申办者:Imperial College London
药物 / 成分:Liraglutide Pen Injector [Victoza]
登记的停止原因(原文):No participants recruited. Not able to recruit due to COVID 19.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-14
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
编号:NCT03807063登记状态:入组前撤回企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:Rivogenlecleucel、Rimiducid
登记的停止原因(原文):Insufficient funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-13
Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality
编号:NCT01805817登记状态:入组前撤回企业 / 申办者:Istanbul Training and Research Hospital
药物 / 成分:YASMIN® (Drospirenone/Ethinyl Estradiol)、The Copper-T is an intrauterine device (IUD)、levonorgestrel-releasing system
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-13
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
编号:NCT03598816登记状态:入组前撤回企业 / 申办者:Washington University School of Medicine
药物 / 成分:Durvalumab、Tremelimumab、TDS-IM v1.0 System、Neoantigen DNA Vaccine
登记的停止原因(原文):FDA Contingencies unresolved
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-13
Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupi vs. Bupi Only Administered as Combined Sciatic and Adductor Canal Nerve Block for Postsurgical Analgesia in Lower Extremity Surgeries
编号:NCT03954639登记状态:入组前撤回企业 / 申办者:Pacira Pharmaceuticals, Inc
药物 / 成分:EXPAREL 13.3Mg/mL Suspension for Injection、Bupivacaine Hydrochloride
登记的停止原因(原文):Sponsor Decision.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-08-13
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
编号:NCT04233697登记状态:入组前撤回企业 / 申办者:Columbia University
药物 / 成分:Copanlisib、Romidepsin
登记的停止原因(原文):Investigator left institution
查看官方原始记录 ↗